Shareholders Equity: The sum of preferred and common equity items.
Takeda Pharmaceutical Co. (TAK) had Shareholders Equity of $48.97B for the most recently reported fiscal quarter, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$18.18B |
|
$13.32B |
|
$81.53B |
|
$99.71B |
|
$13.85B |
|
$31.05B |
|
$36.89B |
|
$50.74B |
|
$48.97B |
|
$-13.56B |
|
|
Shareholders Equity |
$48.97B |
3.17B |
|
| Cash Flow Statement Financials | |
$5.51B |
|
$-2.29B |
|
$-2.97B |
|
$3.02B |
|
$3.26B |
|
$239.75M |
|
$364.58M |
|
$-1.93B |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|